Contrave's future in doubt as US FDA demands another cardiac study
This article was originally published in Scrip
Executive Summary
The future of Orexigen Therapeutics/Takeda's obesity therapy Contrave (naltrexone HCl/bupropion HCl) looks highly uncertain after the US FDA said it wanted a further cardiovascular safety trial before it will approve the product. The request, outlined in a complete response letter, wiped more than 70% off of the US company's share price in early trading on 1 February.